Loading...
•
Jun 30, 2023
Pacira Q2 2023 Earnings Report
Pacira reported second quarter financial results.
Key Takeaways
Pacira BioSciences reported total revenues of $169.5 million for Q2 2023, with a net income of $25.8 million, or $0.51 per share (diluted). EXPAREL net product sales were $135.1 million, ZILRETTA net product sales were $29.3 million, and iovera° net product sales were $4.4 million.
Total revenues were $169.5 million.
EXPAREL net product sales were $135.1 million.
ZILRETTA net product sales were $29.3 million.
Net income was $25.8 million, or $0.51 per share (diluted).
Revenue by Segment
Forward Guidance
Pacira is revising the full-year financial guidance for EXPAREL net product sales to $550 million to $560 million, ZILRETTA net product sales to $110 million to $115 million, Non-GAAP gross margin of 73% to 74%, and Stock-based compensation of $46 million to $49 million. Pacira is reiterating the full-year financial guidance for iovera° net product sales of $17 million to $20 million, Non-GAAP R&D expense of $70 million to $80 million, and Non-GAAP SG&A expense of $220 million to $230 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...